Sheila A. Denton Sells 14,069 Shares of Incyte Co. (NASDAQ:INCY) Stock

Incyte Co. (NASDAQ:INCY) EVP Sheila A. Denton sold 14,069 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the completion of the sale, the executive vice president now owns 25,848 shares of the company’s stock, valued at $1,914,561.36. This trade represents a 35.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Incyte Trading Up 0.4 %

NASDAQ:INCY opened at $73.50 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. Incyte Co. has a 12 month low of $50.35 and a 12 month high of $83.95. The company has a market cap of $14.22 billion, a PE ratio of 272.23, a price-to-earnings-growth ratio of 0.41 and a beta of 0.70. The company has a 50 day simple moving average of $71.77 and a two-hundred day simple moving average of $69.89.

Incyte (NASDAQ:INCY) last posted its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. Research analysts forecast that Incyte Co. will post 4.86 earnings per share for the current year.

Institutional Investors Weigh In On Incyte

Hedge funds have recently modified their holdings of the business. Quintet Private Bank Europe S.A. bought a new stake in shares of Incyte during the 4th quarter valued at $26,000. Global X Japan Co. Ltd. grew its position in shares of Incyte by 144.7% during the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 230 shares during the period. Brooklyn Investment Group bought a new stake in shares of Incyte during the 3rd quarter valued at $30,000. R Squared Ltd bought a new stake in shares of Incyte during the 4th quarter valued at $30,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Incyte during the 3rd quarter valued at $33,000. Institutional investors own 96.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on INCY. Royal Bank of Canada lowered their target price on shares of Incyte from $70.00 to $68.00 and set a “sector perform” rating for the company in a report on Tuesday, February 11th. Wells Fargo & Company lifted their target price on shares of Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. JMP Securities reiterated a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th. StockNews.com lowered shares of Incyte from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Finally, Stifel Nicolaus lifted their target price on shares of Incyte from $75.00 to $77.00 and gave the company a “hold” rating in a report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Incyte currently has an average rating of “Hold” and a consensus target price of $75.25.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.